Pontifax Management 4 G.P. (2015) Ltd. Insider Trading $KROS Keros Therapeutics, Inc.

FREE EMAIL WATCHDOG

Get free email notifications about insider trading for Pontifax Management 4 G.P. (2015) Ltd..

Your email is safe with us.
The service is free and you can unsubscribe at any time.

General | Insider Transactions | Monthly Overview

Get the latest insider transactions of Pontifax Management 4 G.P. (2015) Ltd.. Pontifax Management 4 G.P. (2015) Ltd. is in Eloxx Pharmaceuticals, Inc. ($ELOX) and 10% Owner in Eloxx Pharmaceuticals, Inc. ($ELOX) and 10% Owner in Keros Therapeutics, Inc. ($KROS).

Pontifax Management 4 G.P. (2015) Ltd. in Keros Therapeutics, Inc.

Trading Symbol: KROS
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Pontifax Management 4 G.P. (2015) Ltd.: 10% Owner
Holdings: 2,288,151 shares
Latest Transaction: Nov 19 2020

Last 4 weeks trend: HOLD
Last 3 months trend: HOLD

Latest Insider Trading Transactions of Pontifax Management 4 G.P. (2015) Ltd. in Keros Therapeutics, Inc.

	1 Week	2 Weeks	1 Month	3 Months	6 Months	1 Year	2 Years
No. of Purchases	0	0	0	0	0	0	0
Value of Purchases ($)	0	0	0	0	0	0	0
No. of Sales	0	0	0	0	0	0	0
Value of Sales ($)	0	0	0	0	0	0	0

Sentiment: All, ELOX, KROS

Page: 1

Date	Ticker	Company	Owner	Relationship	Transaction	Code	Cost ($)	Shares	Transaction Value ($)	Total Shares	% Holdings
Nov 19 2020	KROS	Keros Therapeutics ...	Pontifax Management 4 G.P. (20 ...	10% Owner	Buy	P	50.00	6,000	300,000	155,262	149.3 K to 155.3 K (+4.02 %)
Nov 19 2020	KROS	Keros Therapeutics ...	Pontifax Management 4 G.P. (20 ...	10% Owner	Buy	P	50.00	14,400	720,000	1,228,326	1.2 M to 1.2 M (+1.19 %)
Nov 19 2020	KROS	Keros Therapeutics ...	Pontifax Management 4 G.P. (20 ...	10% Owner	Buy	P	50.00	12,966	648,300	1,122,768	1.1 M to 1.1 M (+1.17 %)
Nov 19 2020	KROS	Keros Therapeutics ...	Pontifax Management 4 G.P. (20 ...	10% Owner	Buy	P	50.00	26,634	1,331,700	2,288,151	2.3 M to 2.3 M (+1.18 %)
Apr 13 2020	KROS	Keros Therapeutics ...	Pontifax Management 4 G.P. (20 ...	10% Owner	Option Exercise	C	0.00	36,858	0	0
Apr 13 2020	KROS	Keros Therapeutics ...	Pontifax Management 4 G.P. (20 ...	10% Owner	Option Exercise	C	0.00	79,653	0	0
Apr 13 2020	KROS	Keros Therapeutics ...	Pontifax Management 4 G.P. (20 ...	10% Owner	Option Exercise	C	0.00	88,460	0	0
Apr 13 2020	KROS	Keros Therapeutics ...	Pontifax Management 4 G.P. (20 ...	10% Owner	Option Exercise	C	0.00	163,612	0	0
Apr 13 2020	KROS	Keros Therapeutics ...	Pontifax Management 4 G.P. (20 ...	10% Owner	Option Exercise	C	0.00	68,654	0	0
Apr 13 2020	KROS	Keros Therapeutics ...	Pontifax Management 4 G.P. (20 ...	10% Owner	Option Exercise	C	0.00	91,538	0	0
Apr 13 2020	KROS	Keros Therapeutics ...	Pontifax Management 4 G.P. (20 ...	10% Owner	Option Exercise	C	0.00	82,425	0	0
Apr 13 2020	KROS	Keros Therapeutics ...	Pontifax Management 4 G.P. (20 ...	10% Owner	Option Exercise	C	0.00	169,307	0	0
Apr 13 2020	KROS	Keros Therapeutics ...	Pontifax Management 4 G.P. (20 ...	10% Owner	Option Exercise	C	0.00	737,226	0	0
Apr 13 2020	KROS	Keros Therapeutics ...	Pontifax Management 4 G.P. (20 ...	10% Owner	Option Exercise	C	0.00	663,825	0	0
Apr 13 2020	KROS	Keros Therapeutics ...	Pontifax Management 4 G.P. (20 ...	10% Owner	Option Exercise	C	0.00	1,363,542	0	0
Apr 13 2020	KROS	Keros Therapeutics ...	Pontifax Management 4 G.P. (20 ...	10% Owner	Buy	P	16.00	43,750	700,000	149,262	105.5 K to 149.3 K (+41.46 %)
Apr 13 2020	KROS	Keros Therapeutics ...	Pontifax Management 4 G.P. (20 ...	10% Owner	Buy	P	16.00	105,000	1,680,000	1,213,926	1.1 M to 1.2 M (+9.47 %)
Apr 13 2020	KROS	Keros Therapeutics ...	Pontifax Management 4 G.P. (20 ...	10% Owner	Buy	P	16.00	94,546	1,512,736	1,109,802	1 M to 1.1 M (+9.31 %)
Apr 13 2020	KROS	Keros Therapeutics ...	Pontifax Management 4 G.P. (20 ...	10% Owner	Buy	P	16.00	194,203	3,107,248	2,261,517	2.1 M to 2.3 M (+9.39 %)
Apr 13 2020	KROS	Keros Therapeutics ...	Pontifax Management 4 G.P. (20 ...	10% Owner	Buy	C	0.00	36,858	0	105,512	68.7 K to 105.5 K (+53.69 %)
Apr 13 2020	KROS	Keros Therapeutics ...	Pontifax Management 4 G.P. (20 ...	10% Owner	Buy	C	0.00	79,653	0	1,108,926	1 M to 1.1 M (+7.74 %)
Apr 13 2020	KROS	Keros Therapeutics ...	Pontifax Management 4 G.P. (20 ...	10% Owner	Buy	C	0.00	88,460	0	1,015,256	926.8 K to 1 M (+9.54 %)
Apr 13 2020	KROS	Keros Therapeutics ...	Pontifax Management 4 G.P. (20 ...	10% Owner	Buy	C	0.00	163,612	0	2,067,314	1.9 M to 2.1 M (+8.59 %)
Apr 13 2020	KROS	Keros Therapeutics ...	Pontifax Management 4 G.P. (20 ...	10% Owner	Buy	C	0.00	68,654	0	68,654	0 to 68.7 K
Apr 13 2020	KROS	Keros Therapeutics ...	Pontifax Management 4 G.P. (20 ...	10% Owner	Buy	C	0.00	91,538	0	1,029,273	937.7 K to 1 M (+9.76 %)
Apr 13 2020	KROS	Keros Therapeutics ...	Pontifax Management 4 G.P. (20 ...	10% Owner	Buy	C	0.00	82,425	0	926,796	844.4 K to 926.8 K (+9.76 %)
Apr 13 2020	KROS	Keros Therapeutics ...	Pontifax Management 4 G.P. (20 ...	10% Owner	Buy	C	0.00	169,307	0	1,903,702	1.7 M to 1.9 M (+9.76 %)
Apr 13 2020	KROS	Keros Therapeutics ...	Pontifax Management 4 G.P. (20 ...	10% Owner	Buy	C	0.00	737,226	0	937,735	200.5 K to 937.7 K (+367.68 %)
Apr 13 2020	KROS	Keros Therapeutics ...	Pontifax Management 4 G.P. (20 ...	10% Owner	Buy	C	0.00	663,825	0	844,371	180.5 K to 844.4 K (+367.68 %)
Apr 13 2020	KROS	Keros Therapeutics ...	Pontifax Management 4 G.P. (20 ...	10% Owner	Buy	C	0.00	1,363,542	0	1,734,395	370.9 K to 1.7 M (+367.68 %)

Page: 1